Abstract
Lp(a) is an independent risk factor for cardiovascular disease risk. Statins increase low-density lipoprotein receptor (LDLR) activity but have little effect on Lp(a), while the PCSK9-inhibitor evolocumab consistently reduces Lp(a) 20-30% by a yet unknown mechanism. We investigated the possible role
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
